Uniform Care of Testicular Cancer Overcame Sociodemographic Factors
Guideline-directed care resulted in equivalent outcomes independent of hospital setting.
Guideline-directed care resulted in equivalent outcomes independent of hospital setting.
A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.
Malignant recurrence rate was 1.3 percent at two years for one-cycle BE500P in high-risk early-stage disease.
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.
A study of twins with 22 980 individuals suggested that the familial risk for testicular cancer may be dramatically underestimated.
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) important for rendering patients with testicular cancer disease-free.
Patients with testicular cancer who received chemotherapy, but not surgery, were more likely to die from cardiovascular disease (CVD).
Patients presenting with stage I seminoma who received adjuvant carboplatin following inguinal orchidectomy have excellent prognosis.